[
  {
    "ts": null,
    "headline": "UBS Lowers Price Target On Regeneron Pharmaceuticals, Inc. (REGN).",
    "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. UBS has maintained its Neutral rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and reduced its price objective from $633 to $560 on June 5, noting mixed corporate updates and recent pipeline advancements. The Phase 2 COURAGE study interim readout, […]",
    "url": "https://finnhub.io/api/news?id=8f9cd02409779ca9b5e8a8b9fe99dc6e628be7ecdabd4d9158e14a53e7e84552",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750656858,
      "headline": "UBS Lowers Price Target On Regeneron Pharmaceuticals, Inc. (REGN).",
      "id": 135482105,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. UBS has maintained its Neutral rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and reduced its price objective from $633 to $560 on June 5, noting mixed corporate updates and recent pipeline advancements. The Phase 2 COURAGE study interim readout, […]",
      "url": "https://finnhub.io/api/news?id=8f9cd02409779ca9b5e8a8b9fe99dc6e628be7ecdabd4d9158e14a53e7e84552"
    }
  },
  {
    "ts": null,
    "headline": "The Top 5 Analyst Questions From Regeneron’s Q1 Earnings Call",
    "summary": "Regeneron’s first quarter was marked by a negative market reaction, as revenue and non-GAAP earnings fell short of Wall Street’s expectations. The primary driver of underperformance was a steep revenue decline in the company’s retinal franchise, particularly EYLEA, which management attributed to increased competition from low-cost alternatives and reduced patient affordability due to a funding gap at co-pay assistance foundations. CEO Leonard Schleifer described the quarter as “mixed,” noting th",
    "url": "https://finnhub.io/api/news?id=bd7189b09e6efcbcc2171821caf59cf8f345141e03d17917d0ee24948e379605",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750651161,
      "headline": "The Top 5 Analyst Questions From Regeneron’s Q1 Earnings Call",
      "id": 135482106,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron’s first quarter was marked by a negative market reaction, as revenue and non-GAAP earnings fell short of Wall Street’s expectations. The primary driver of underperformance was a steep revenue decline in the company’s retinal franchise, particularly EYLEA, which management attributed to increased competition from low-cost alternatives and reduced patient affordability due to a funding gap at co-pay assistance foundations. CEO Leonard Schleifer described the quarter as “mixed,” noting th",
      "url": "https://finnhub.io/api/news?id=bd7189b09e6efcbcc2171821caf59cf8f345141e03d17917d0ee24948e379605"
    }
  },
  {
    "ts": null,
    "headline": "Q1 Rundown: Regeneron (NASDAQ:REGN) Vs Other Immuno-Oncology Stocks",
    "summary": "Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Regeneron (NASDAQ:REGN) and its peers.",
    "url": "https://finnhub.io/api/news?id=83b1c6018ede56bff622b4187ef63d32c2ba2032da387a6c4e2f1cdfb1067fe4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750649501,
      "headline": "Q1 Rundown: Regeneron (NASDAQ:REGN) Vs Other Immuno-Oncology Stocks",
      "id": 135482107,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Regeneron (NASDAQ:REGN) and its peers.",
      "url": "https://finnhub.io/api/news?id=83b1c6018ede56bff622b4187ef63d32c2ba2032da387a6c4e2f1cdfb1067fe4"
    }
  }
]